Skip to main content
logo
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
460.87
+4.18 (0.92%)
At close: Mar 9, 2026, 4:00 PM EDT
494.70
+33.83 (7.34%)
After-hours: Mar 9, 2026, 5:25 PM EDT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Trikafta / Kaftrio Revenue
10.31B10.24B
Trikafta / Kaftrio Revenue Growth
0.72%14.47%
Alyftrek Revenue
837.80M-
Casgevy Revenue
115.80M10.00M
Casgevy Revenue Growth
1058.00%-
Journavx Revenue
59.60M-
Other Product Revenue
820.10M781.50M
Other Product Revenue Growth
4.94%-15.47%
Net Product Revenue
11.97B11.02B
Net Product Revenue Growth
8.63%11.66%
Other Collaborative and Royalty Revenue
30.70M-
Revenue (Total)
12.00B11.02B
Revenue (Total) Growth
8.90%11.66%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Other Collaborative and Royalty Revenue
30.70M-
United States Product Revenue
7.55B6.68B
United States Product Revenue Growth
12.92%10.67%
Outside of United States Product Revenue
4.45B4.34B
Outside of United States Product Revenue Growth
2.71%13.23%
Revenue (Other)
-30.70M-
Revenue (Total)
12.00B11.02B
Revenue (Total) Growth
8.90%11.66%
Updated Feb 12, 2026. Data Source: Fiscal.ai.